Dayvobet ointment 30g

Description

Composition
Active substance:
calcipotriol monohydrate 0.052 mg, equivalent to 0.050 mg of calcipotriol;
0.643 mg of betamethasone dipropionate, betamethasone equivalent to 0.500 mg;
Excipients:
paraffin liquid (containing about 10 ppm alpha-tocopherol) 30.0 mg, polypropylene glycol stearate (containing about 0.1% BHT), 50.0 mg, alpha-tocopherol 0.02 mg, white soft paraffin (containing about 10 ppm alpha-tocopherol) and 1.0 g
Description:
Homogeneous ointment from almost white to pale yellow in color.
Product form:
Ointment for external use.
30 g of product in an aluminum tube, coated inside with a polyethylene screw cap. 1 tube together with instructions for use in a cardboard box.
Contraindications
Diseases accompanied by abnormal calcium metabolism
Hypersensitivity to any component of the drug
Severe renal and hepatic failure
Viral (including herpes, or chicken pox), fungal, bacterial and parasitic skin infections, rosacea, rosacea, acne vulgaris, perioral dermatitis, cutaneous manifestations of tuberculosis and syphilis, skin atrophy, skin ulcers, increased fragility of the skin vessels, ichthyosis, perianal and genital itch
Erythrodermic psoriasis, guttate, exfoliative, pustular psoriasis
Experience of using Dayvobet® the drug in children younger than 18 years of absence.
Indications
Chronic plaque psoriasis vulgaris.
Interaction with other drugs
It is not known.
Overdose
Symptoms: increased calcium in the blood; suppression function gipofizarnonadpochechnikovoy system with the development of reversible secondary adrenal insufficiency.
Treatment: stop the drug and symptomatic therapy. In cases of chronic toxicity of corticosteroids should be withdrawn gradually.
pharmachologic effect
Pharmacological group:
means for treating psoriasis.
Pharmacodynamics:
Calcipotriol – a synthetic analogue of the active metabolite of vitamin D. It is inhibition of proliferation of keratinocytes and accelerates their morphological differentiation.
Betamethasone – glucocorticosteroid (GCS) for external use; has a local anti-inflammatory, antipruritic, vasoconstrictive and immunosuppressive effect, however, the exact mechanisms of anti-inflammatory activity of topical steroids is not completely clear.
Pharmacokinetics:
When the drug topically Dayvobet® calcipotriol and betamethasone absorption through intact skin is less than 1%. When applying the drug on psoriatic plaques and under occlusive dressings increases the absorption of betamethasone. Since the skin creates a depot preparation, its elimination from the skin occurs within a few days. Betamethasone is metabolized in the liver and in the kidneys to form glucuronides and ethersulfates, excretion via the kidneys and intestine.
Pregnancy and breast-feeding
Dayvobet® safety of the drug during pregnancy and lactation has not been established, so the drug can be used only if the potential benefit to the mother outweighs the risk to the fetus or child.
Conditions of supply of pharmacies
Leave without prescription
side effects
Side effects are classified according to frequency of occurrence:
the most common> 1/10, frequent> 1/100 and
special instructions
Do not apply the drug on the skin, mucous membranes and scalp. Do not apply the drug on the periorbital region due to the possible development of cataracts and increased intraocular pressure. After application of the ointment should be thoroughly wash your hands.
The risk of hypercalcemia in compliance with the recommended dosing regimen is minimal. However, when using Dayvobet® drug in doses exceeding the recommended maximum weekly dose (100 g), may develop hypercalcemia, passing rapidly while reducing its dosage or cancellation.
Dayvobet® contains potent corticosteroids, therefore not recommended for concomitant treatment with other glucocorticosteroids.
It is recommended to avoid use of the drug over extensive areas of the skin, comprising more than 30% of the body surface, and also under occlusive bandage applied to the skin folds, because it increases the likelihood of systemic absorption of corticosteroids and systemic adverse reactions.
Side effects such as suppression of hypothalamic-pituitary-adrenal system development reversible secondary adrenal insufficiency or aggravation of diabetes mellitus associated with systemic administration of corticosteroids may also occur with prolonged use of corticosteroids include, owing systemic absorption. Complication psoriasis secondary infection, antibiotic therapy should be performed, and when exacerbating cancel Dayvobet® infection.
During treatment Dayvobet® doctors recommend patients to limit or avoid excessive exposure to either natural or artificial sunlight.
Calcipotriol topical should be used with UV – light only if the physician and patient consider that the potential benefits outweigh the potential risks.
The effect on the ability to drive vehicles and mechanisms
Does not affect.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children.
Once opened, store the drug 6 months
Dosing and Administration
Outwardly. In adults, a thin layer of ointment applied to the affected skin 1 time per day. The maximum daily dose of not more than 15 g; Maximum weekly dose should not exceed 100, the recommended duration of treatment 4 weeks. Then Dayvobet® can be used repeatedly under medical supervision. The area of ​​application of the drug should not exceed 30% of the body surface.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist